Thrombotic complications in childhood acute lymphoblastic leukemia: A meta-analysis of 17 prospective studies comprising 1752 pediatric patients

Blood

Volumn 108, Issue 7, 2006, Pages 2216-2222

  Caruso, Vanesa ^b   Iacoviello, Licia ^a   Di Castelnuovo, Augusto ^b   Storti, Sergio ^b   Mariani, Guglielmo ^b   De Gaetano, Giovanni ^b   Donati, Maria Benedetta ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTITHROMBIN III; ASPARAGINASE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CLINICAL TRIAL; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOSIS;

EID: 33749332107     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-015511     Document Type: Article

References (114)

1. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Europ J Cancer Care. 2005;14:53-62.
2. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukaemia: epidemiology of thrombosis in children with acute lymphoblastic leukaemia. Thrombosis Res. 2003;111:125-131.
3. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukaemia: pathogenesis of thrombosis in children with acute lymphoblastic leukaemia: effect of the disease and therapy. Thrombosis Res. 2003;111:199-212.
4. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukaemia: pathogenesis of thrombosis in children with acute lymphoblastic leukaemia: effect of host environment. Thrombosis Res. 2003;111:321-327.
5. Jaime-Perez JC, Gomez-Almaguer D. The complex nature of the prothrombotic state in acute lymphoblastic leukemia of childhood. Haematologica. 2003;88:ELT25.
6. Alberts SR, Bretscher M, Wiltsie JC, O'Neill BP, Mokri B, Witzig TE. Thrombosis related to the use of L-Asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement. Leuk Lymphoma. 1999;32:489-496.
7. Musa MO, Al-Fair F, Al-Mohareb F, Al-Saeed H, Aljurf M. Cryoprecipitate-induced mesenteric venous thrombosis during L-Asparaginase therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2001;40:429-431.
8. Pui CH, Chesney CM, Bergum PW, Jackson CW, Rapaport SI. Lack of pathogenetic role of protein C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukemia. Br J Haematol. 1986;64:283-290.
9. Lockman LA, Mastri A, Priest JR, Nesbit M. Dural venous sinus thrombosis in acute lymphoblastic leukemia. Pediatrics. 1980;66:943-947.
10. Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, Bohles H. Cerebrovascular complications of L-Asparaginase in the therapy of acute lymphoblastic leukemia. J Ped Hematol Oncol. 2003;25:484-487.
11. Pui CH, Jackson CW, Chesney CM, Abildgaard CF. Involvement of von Willebrand factor in thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. Am J Hematol. 1987;25:291-298.
12. Kucuk O, Kwaan HC, Gunnar W, Vazquez RM. Thromboembolic complicatins associated with L-Asparaginase therapy. Cancer. 1985;55:702-706.
13. Ott N, Ramsay NK, Priest JR, et al. Sequelae of thrombotic or hemorrhagic complications following L-Asparaginase therapy for childhood lymphoblastic leukemia. Am J Ped Hematol Oncol. 1988;10:191-195.
14. Velenga E, Broekmans AW, Kluft C. Thrombotic complications during L-Asparaginase related to protein C deficiency [letter]. Thromb Haemostas. 1985;53:443.
15. Priest JR, Ramsay NK, Latchaw RE et al. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer. 1980;46:1548-1554.
16. Pitney WR, Phadke KP, Dean S. AT III deficiency during L-asp therapy. Lancet. 1980;1:493-494.
17. Steinherz PG, Miller LP, Ghavimi F, Allen JC, Miller DR. Dural sinus thrombosis in children with ALL. JAMA. 1981;246:2837-2839.
18. Chojnowski K, Wawrzyniak E, Trelinski J, Niewiarowska J, Cierniewski C. Assessment of coagulation disorders in patients with acute leukemia before and after cytostatic treatment. Leuk Lymphoma. 1999;36:77-84.
19. Uszynski M, Osinska M, Zekanowska E, Ziolkowska E. Children with acute lymphoblastic leukemia: is there any subgroup of children without elevated thrombin generation? a preliminary study utilizing measurements of thrombin-antithrombin III complexes. Med Sci Monit. 2000;6:108-111.
20. Bauer KA, Teitel JM, Rosenberg RD. L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state. Thromb Res. 1983;29:437-442.
21. Saito M, Asakura H, Jokaji H, et al. Changes in hemostatic and fibrinolytic proteins in patients receiving L-asparaginase therapy. Am J Hematol. 1989;32:20-23.
22. de Stefano V, Gugliotta L, Mazzucconi MG, Leone G, Mandelli F. Hypercoagulability during induction therapy of acute lymphoblastic leukemia is of scarce clinical relevance: Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto. Blood. 1993;81:2468-2469.
23. Sarris A, Cortes J, Kantarjian H, et al. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma. 1996;21:85-92.
24. Solano C, Lopez J, Gomez N, Fernandez-Ranada JM. Acute lymphoblastic leukemia: hypofibrinogenemia with a low incidence of clinical complications is often found during induction remission therapy. Blood. 1992;80:1366-1368.
25. Ramsay NK, Coccia PF, Krivit W, Nesbit ME, Edson JR. The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia. Cancer. 1977;40:1398-1401.
26. Nowak-Gottl U, Rath B, Binder M, et al. Inefficacy of fresh frozen plasma in the treatment of L-Asparaginase-induced coagulation factor deficiencies during all induction therapy. Haematologica. 1995;80:451-453.
27. Arico M, Gamba G, Raiteri E, Montani N, De Amici M, Burgio R. Clotting abnormalities in children during maintenance chemotherapy for acute lymphoblastic leukemia. Haematologica. 1991;76:472-474.
28. Hoelzer D, Thiel E, Loffler H, et al. Intensified therapy in acute lymphoblastic and acute undifferentiated leukaemia in adults. Blood. 1984;64:38-47.
29. Halton JM, Mitchell LG, Vegh P, Eves M, Andrew ME. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-Asparaginase. Am J Hematol. 1994;47:157-161.
30. Bassan R, Battista R, Rohatiner AZS, et al. Treatment of adult acute lymphoblastic leukaemia over a 16 year period. Leukemia. 1992,6:186-190.
31. Oner AF, Gurgey A, Kirazli S, Okur H, Tunc B. Changes of hemostatic factors in children with acute lymphoblastic leukaemia receiving combined chemotherapy including high dose methylprednisolone and L-Asparaginase. Leuk Lymphoma. 1999;33:361-364.
32. Belmonte MM, Guliotta L, Delvos U, et al. A regimen for antithrombin III substitution in patients with acute lymphoblastic leucemia under treatment with L-asparaginase. Haematologica. 1991;76:209-214.
33. Sallan SE, Hitchcock-Bryan S, Gelber R, Robert Cassady J, Frei E III, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukaemia. Cancer Res. 1983;43:5601-5607.
34. Eden OB, Shaw MP, Lilleyman JS, Richards S. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. Med Pediatr Oncol. 1990;18:497-502.
35. Steinherz PG, Gaynon P, Miller DR, et al. Improved disease-free survival of children with acute lymphoblastic leukaemia at high risk for early relapse with the New York regimen: a new intensive therapy protocol: a report from the Children's Cancer Study Group. J Clin Oncol. 1986;4:744-752.
36. Pui CH, Jackson CW, Chesney C, et al. Sequential changes in platelet function and coagulation in leukemic children treated with L-Asparaginase, prednisone and vincristine. J Clin Oncol. 1983;1:380-385.
37. Lister TA, Whitehouse JM, Beard ME, et al. Combination chemotherapy for acute lymphoblastic leukaemia in adults. Br Med J. 1978;1:199-203.
38. Andrew M, Brooker L, Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. Blood Coag Fibrinolysis. 1994;5:S24-S36.
39. Leone G, Sica S, Chiusolo P, Teofili L, De Stefano V. Blood cell disease and thrombosis. Haematologica. 2001;86:1236-1244.
40. Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukaemia. Seminars Thromb Hemost. 2001;27:593-604.
41. Dreyfus M. Thrombotic risk in children with acute lymphoblastic leukaemia. Ped Hematol Oncol. 2001;18:233-234.
42. Nowak-Gottl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood. 1999;93:1595-1599.
43. Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost. 2000;83:840-843.
44. Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia: results of the PAARKA study. Thromb Haemost. 2003;90:235-244.
45. Male C, Chait P, Ginsberg JS, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study: Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost. 2002;87:593-598.
46. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1217.
47. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organization for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002;99:2734-2739.
48. Barbui T, Finazzi G, Falanga A, Battista R, Bassan R. Bleeding and thrombosis in acute lymphoblastic leukemia. Leuk Lymphoma. 1993;11:43-47.
49. Sarris AH, Kempin S, Berman E, et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood. 1992;79:1305-1310.
50. Gugliotta L, Mazzucconi MG, Leone G, et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study: The GIMEMA Group. Eur J Haematol. 1992;49:63-66.
51. Conard J, Cazenave B, Maury J, Horellou MH, Samama M. L-asparaginase, antithrombin III, and thrombosis [letter]. Lancet. 1980;1:1091.
52. Ziegler S, Sperr WR, Knobl P, et al. Symptomatic venous thromboembolism in acute leukemia: incidence, risk factors, and impact on prognosis. Thromb Res. 2005;115:59-64.
53. Beinart G, Damon L. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol. 2004;77:331-335.
54. Elliott MA, Wolf RC, Hook CC, et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma. 2004;45:1545-1549.
55. Gugliotta L, D'Angelo A, Mattioli Belmonte M, et al. Tura S Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo. Br J Haematol. 1990;74:465-470.
56. Vigano'D'Angelo S, Gugliotta L, Mattioli Belmonte M, Cascione ML, Pattarini E, D'Angelo A. L-asparaginase treatment reduces the anticoagulant potential of the protein C system without affecting vitamin K-dependent carboxylation. Thromb Res. 1990;59:985-994.
57. Rodeghiero F, Castaman G, Dini E. Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation. Thromb Res. 1990;57:31-38.
58. Mazzucconi MG, Gugliotta L, Leone G, et al. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase: a GIMEMA study. Blood Coagul Fibrinolysis. 1994;5:23-28.
59. Carlsson H, Stockelberg D, Tengborn L, Braide I, Carneskog J, Kutti J. Effects of Erwinia-asparaginase on the coagulation system. Eur J Haematol. 1995;55:289-293.
60. Nocentini F, Gugliotta L, Catani L, et al. Negligible hemostatic toxicty of intermediate-dose erwinase in adult patients with acute lymphoblastic leucemia: preliminary data. Haematologica. 1994;79:546-549.
61. Liebman HA, Wada JK, Patch MJ, McGehee W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer. 1982;50:451-456.
62. Barbui T, Finazzi G, Vigano S, Mannucci PM. L-Asparaginase lowers protein C antigen [letter]. Thromb Haemostas. 1984;52:216.
63. Castaman G, Rodeghiero F, Dini E. Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia. Haematologica. 1990;75:567-569.
64. Leone G, Gugliotta L, Mazzucconi MG, et al. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study. Thromb Haemost. 1993;69:12-15.
65. Barbui T, Rodeghiero F, Meli S, Dini E. Fatal pulmonary embolism and antithrombin III deficiency in adult lymphoblastic leukaemia during L-asparaginase therapy. Acta Haematol. 1983;69:188-191.
66. De Stefano V, Sora F, Rossi E, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost. 2005;3:1985-1992.
67. Bassan R, Battista R, D'Emilio A, et al. Long-term results of the HEAVD protocol for adult acute lymphoblastic leukaemia. Eur J Cancer. 1991;27:441-447.
68. Castaman G, Rodeghiero F. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis: pilot study in 10 patients with acute lymphoblastic leukemia. Haematologica. 1993;78:57-60.
69. Pogliani EM, Parma M, Baragetti I, et al. L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy. Acta Haematol. 1995;93:5-8.
70. Mitchell LG, Andrew M, Hanna K, et al. Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA): a prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-Asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer. 2003;97:508-516.
71. Wermes C, von Depka Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora KW. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr. 1999;158:S143-S146.
72. Mitchell L, Hoogendoom H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-Asparaginase-induced antithrombin III deficiency. Blood. 1994;83:386-391.
73. Nowak-Gottl U, Ahike E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone verss dexamethasone administration. Blood. 2003;101:2529-2533.
74. Giordano P, Del Vecchio GC, Santoro N, et al. Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotype subgroups. Ped Hematol Oncol. 2000;17:667-672.
75. Elhasid R, Lanir N, Sharon R, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrin. 2001;12:367-370.
76. Nowak-Gottl U, Heinecke A, von Kries R, Nurnberger W, Munchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res. 2001;103:165-172.
77. Nowak-Gottl U, Aschka I, Koch HG, et al. Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia: the need for a prospective multicentre study. Blood Coagul Fibrinolysis. 1995;6:761-764.
78. Shapiro AD, Clarke SL, Christian JM, Odom LF, Hathaway WE. Thrombosis in children receiving L-asparaginase: determining patients at risk. Am J Pediatr Hematol Oncol. 1993;15:400-405.
79. Pui CH, Chesney CM, Weed J, Jackson CW. Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone- vincristine therapy for leukemia. J Clin Oncol. 1985;3:1266-1272.
80. Abshire TC, Gold SH, Odom LF, Carson SD, Hathaway WE. The coagulopathy of childhood leukemia: thrombin activation or primary fibrinolysis? Cancer. 1990;66:716-721.
81. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986;315:657-663.
82. Nowak-Gottl U, Ahlke E, Schulze-Westhoff P, Boos J. Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation. Br J Haematol. 1996;95:123-126.
83. Nowak-Gottl U, Werber G, Ziemann D, Ahlke E, Boos J. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica. 1996;81:127-131.
84. Miniero R, Pastore G, Saracco P, et al. Hemostatic changes in children with acute lymphoblastic leukemia treated according to two different Lasparaginase schedules. Am J Pediatr Hematol Oncol. 1986;8:116-120.
85. Nowak-Gottl U, Ahlke E, Klosel K, Jurgens H, Boos J. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations. Eur J Pediatr. 1997;156:848-850.
86. Risseeuw-Appel IM, Dekker I, Hop WC, Hahlen K. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study. Med Pediatr Oncol. 1994;23:335-343.
87. Zaunschirm A, Muntean W. Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1986;3:19-25.
88. Bezeaud A, Drouet L, Leverger G, Griffin JH, Guillin MC. Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. J Pediatr. 1986;108:698-701.
89. Priest JR, Ramsay NK, Bennett AJ, Krivit W, Edson JR. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr. 1982;100:990-995.
90. Nowak-Gottl U, Kuhn N, Wolff JE, et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol. 1996;56:35-38.
91. Semeraro N, Montemurro P, Giordano P, et al. Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukaemia. Thromb Haemost. 1990;64:38-40.
92. Legnani C, Palareti G, Pession A, et al. Intravascular coagulation phenomena associated with prevalent fall in fibrinogen and plasminogen during L-asparaginase treatment in leukemic children. Haemostasis. 1988;18:179-186.
93. O'Meara A, Daly M, Hallinan FH. Increased antithrombin III concentration in children with acute lymphatic leukaemia receiving L-asparaginase therapy. Med Pediatr Oncol. 1988;16:169-174.
94. Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner ME, Forman EN. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol. 1987;5:811-817.
95. Totan M, Dagdemir A, Ak AR, Albayrak D, Kucukoduk S. Effects of high-dose methotrexate on the hemostatic system in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 2001;36:429-433.
96. Athale U, Mah D, Davidson A, Nagel K, Odame I, Chan AKC. Thromboembolism in children with acute lymphoblastic leukemia treated on Dana Farber Cancer Institute Protocols: effect of age and risk stratification of ALL. Med Ped Oncol. 2003;41:310.
97. Mathew LG, Ortin M, Pinkerton CR. Thrombotic complications in children treated for ALL: a single centre experience. Med Ped Oncol. 2003;41:310.
98. Giordano P, Santoro N, Del Vecchio GC, Rizzari C, Masera G, De Mattia D. T-immunophenotype is associated with an increased prevalence of thrombosis in children with acute lymphoblastic leukemia: a retrospective study. Haematologica. 2003;88:1079-1080.
99. Hongo T, Okada S, Ohzeki T, et al. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: a retrospective study by the JACLS. Pediatrics Intern. 2002;44:293-299.
100. Packer RJ, Rorke LB, Lange BJ, Siegel KR, Evans AE. Cerebrovascular accidents in children with cancer. Pediatrics. 1985;76:194-201.
101. Sutor AH, Mall V, Thomas KB. Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol. Klin Padiatr. 1999;211:201-204.
102. Priest JR, Ramsay NK, Steinherz PG, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 1982;100:984-989.
103. Martin DO, Austin H. Exact estimates for a rate ratio. Epidemiology. 1996;7:29-33.
104. Alessio MG, Falanga A, Consonni R, et al. Cancer procoagulant in acute lymphoblastic leukemia. Eur J Haematol. 1990;45:78-81.
105. Donati MB, Falanga A. Pathogenesis of thrombosis in cancer. Hematol J. 2003;4:63-67.
106. Shlebak AA, Smith DB. Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy. Cancer Chemother Pharmacol. 1997;39:462-466.
107. Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 2004;164:190-194.
108. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-722.
109. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83:1251-1257.
110. van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr. 2001;139:676-681.
111. Demopoulos A, DeAngelis LM. Neurologic complications of leukaemia. Curr Opin Neurol. 2002;15:691-699.
112. Jan Stam MD. Thrombosis of the cerebral veins and sinuses. New Engl J Med. 2005;352:1791-1798.
113. Gabrielle deVeber MD, Maureen Andrew MD, Coleen Adams MB, et al. Cerebral sinovenous thrombosis in children. New Engl J Med. 2001;345:417-423.
114. Alving BM, Francis CW, Hiatt WR, Jackson MR. Consultations on patients with venous or arterial diseases. Hematology (Am Soc Hematol Educ Program). 2003:540-558.